Supernus Pharmaceuticals Files 8-K

TL;DR

SUPERNUS FILES 8-K - STANDARD DISCLOSURE, NO NEW INFO.

AI Summary

Supernus Pharmaceuticals, Inc. filed an 8-K on May 23, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements for this date.

Why It Matters

This 8-K filing serves as a standard disclosure for Supernus Pharmaceuticals, Inc., indicating that the company is meeting its reporting obligations with the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events, financial results, or significant changes that would impact the company's risk profile.

Key Players & Entities

• Supernus Pharmaceuticals, Inc. (company) — Registrant
• May 23, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Rockville, MD (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto

Filing Documents

• supn-20240523.htm (8-K) — 29KB
• ex99105-23x2024.htm (EX-99.1) — 28KB
• image_0a.jpg (GRAPHIC) — 5KB
• 0001356576-24-000034.txt ( ) — 193KB
• supn-20240523.xsd (EX-101.SCH) — 2KB
• supn-20240523_lab.xml (EX-101.LAB) — 21KB
• supn-20240523_pre.xml (EX-101.PRE) — 12KB
• supn-20240523_htm.xml (XML) — 3KB

01 Regulation FD

Item 7.01 Regulation FD. On May 23, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. The Company will host a webcast and conference call at 4:30 p.m. Eastern Time on Thursday, May 23, 2024, to review the interim data. A live webcast with presentation slides will be available at www.supernus.com. The webcast and presentation slides will be archived on the Company's website for 60 days following the live call. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing. This Current Report on Form 8-K contains "forward-looking statements" that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as "believe," "expect," "intend," "may," "will," "should," or "anticipate" or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus' ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated May 23, 2024 furnished as an Exhibit pursuant to Item 8.01 hereof. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: May 23, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3